内容紹介
Clinical Trial of a Seven-Peptide Vaccine and Tegafur-Uracil/Leucovorin as Combination Therapy for Advanced Colorectal Cancer
Summary
We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer. These antigenic peptides were derived from 5 proteins identified as cancer-testis antigens(ring finger protein 43[RNF43], translocase of outer mitochondrial membrane 34[TOMM34], maternal embryonic leucine zipper kinase[MELK], forkhead box M1[FOXM1], and holliday junction recognition protein[HJURP])and 2 vascular endothelial growth factor receptors(VEGFR1 and VEGFR2). Thirty patients with advanced colorectal cancer were enrolled. We found that 25 patients had Grade 1 injection-site redness/induration and 1 patient had Grade 3 anaphylaxis. Tumor imaging revealed that 3 patients had a partial response(PR), 15 had stable disease(SD)and 12 had progressive disease(PD). This trial showed that treatment with the seven-peptide vaccine and UFT/LV was well tolerated and feasible for advanced colorectal cancer.
要旨
cDNAマイクロアレイ法によって,多種類の癌において新規腫瘍関連抗原が同定され,これら由来のペプチドを用いて臨床試験が進んでいる。われわれは,進行再発大腸癌に対する7種ペプチドワクチン+UFT/LV併用療法による臨床試験を計画し,30例が登録された。有害事象として25例にGrade 1の皮膚反応がみられ,1例にGrade 3のアナフィラキシーショックがみられたが迅速な処置により速やかに改善した。腫瘍縮小効果では,3例PR,15例SD,12例でPDという結果が得られた。7種ペプチドワクチン+UFT/LV併用療法は安全に施行でき,臨床効果の点からも期待のもてる治療と考えられた。
目次
Summary
We conducted a clinical trial of a seven-peptide vaccine in combination with tegafur-uracil/Leucovorin for advanced colorectal cancer. These antigenic peptides were derived from 5 proteins identified as cancer-testis antigens(ring finger protein 43[RNF43], translocase of outer mitochondrial membrane 34[TOMM34], maternal embryonic leucine zipper kinase[MELK], forkhead box M1[FOXM1], and holliday junction recognition protein[HJURP])and 2 vascular endothelial growth factor receptors(VEGFR1 and VEGFR2). Thirty patients with advanced colorectal cancer were enrolled. We found that 25 patients had Grade 1 injection-site redness/induration and 1 patient had Grade 3 anaphylaxis. Tumor imaging revealed that 3 patients had a partial response(PR), 15 had stable disease(SD)and 12 had progressive disease(PD). This trial showed that treatment with the seven-peptide vaccine and UFT/LV was well tolerated and feasible for advanced colorectal cancer.
要旨
cDNAマイクロアレイ法によって,多種類の癌において新規腫瘍関連抗原が同定され,これら由来のペプチドを用いて臨床試験が進んでいる。われわれは,進行再発大腸癌に対する7種ペプチドワクチン+UFT/LV併用療法による臨床試験を計画し,30例が登録された。有害事象として25例にGrade 1の皮膚反応がみられ,1例にGrade 3のアナフィラキシーショックがみられたが迅速な処置により速やかに改善した。腫瘍縮小効果では,3例PR,15例SD,12例でPDという結果が得られた。7種ペプチドワクチン+UFT/LV併用療法は安全に施行でき,臨床効果の点からも期待のもてる治療と考えられた。